Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AMT-260
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Uniqure
Deal Size : $298.1 million
Deal Type : Acquisition
Details : Under the license and collaboration agreement, REGENXBIO received equity in Corlieve and is eligible to receive milestone payments and royalties on net sales of AMT-260.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $54.6 million
June 22, 2021
Lead Product(s) : AMT-260
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Uniqure
Deal Size : $298.1 million
Deal Type : Acquisition
Reset All
